Abstract
Neuroendocrine tumours (NETs) of the urinary tract are rare, and the urinary bladder is the the most common primary site. Primary ureteric NET is rarer with under 80 cases reported in the literature thus far. Most of these tumours are of the high-grade small cell neuroendocrine carcinoma subtype, which has a worse prognosis. Neoadjuvant chemotherapy has a proven role in the management of NET of the bladder as it downstages the tumour, which may add to significant recurrence-free survival and overall survival. We report the successful management of a patient with locally advanced small cell neuroendocrine carcinoma of the ureter, who had a pathological complete response after neoadjuvant chemotherapy with etoposide and cisplatin. He subsequently received adjuvant chemotherapy followed by radiation and is recurrence-free at a follow-up of 1 year.
Reference22 articles.
1. Small cell carcinoma of the upper urinary tract (UUT-SCC): Report of a rare entity and systematic review of the literature
2. Atypical carcinoid neuroendocrine tumor of the ureter: a case report and literature review;Yuen;Surg J,2018
3. Systematic review and two new cases of primary upper urinary tract neuroendocrine carcinomas;Nakasato;Cancer Treat Res Commun,2018
4. Neuroendocrine carcinoma of the ureter: a case report and literature review;Wang;Oncol Lett,2016
5. Walther PJ . Adjuvant/neo-adjuvant etoposide/cisplatin and cystectomy for management of invasive small cell carcinoma of the bladder. J Urol 2002;167:285 https://scholar.google.com/scholar_lookup?journal=J+Urol&title=Adjuvant/neo-adjuvant+etoposide/cisplatin+and+cystectomy+for+management+of+invasive+small+cell+carcinoma+of+the+bladder&author=PJ+Walther&volume=167&publication_year=2002&pages=285&pmid=11743341&
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献